Kneat Recognised as Leader in G2 Pharma and Biotech Fall 2025 Grid Reports
Kneat (OTCQX: KSIOF), a leader in validation and quality process digitization, has achieved top rankings in G2's Fall 2025 Pharma and Biotech Software category reports. The company secured leadership positions in three categories with an impressive G2 Satisfaction Score of 98/100, surpassing the second-ranked company by 20 points.
The company earned leadership recognition in the Grid® Report, Relationship Index, and Mid-Market Grid® Report for Pharma and Biotech. Additionally, Kneat ranked second in the G2 Pharma and Biotech Usability Index, demonstrating strong performance in administration, ease of use, and requirements fulfillment.
Kneat (OTCQX: KSIOF), leader nella validazione e digitalizzazione dei processi di qualità, ha ottenuto posizioni di rilievo nei report di Fall 2025 di G2 per Pharma e Biotech Software. L'azienda ha conquistato posizioni di leadership in tre categorie con un impressionante Voto di Soddisfazione G2 di 98/100, superando di 20 punti la seconda classificata.
L'azienda ha ottenuto riconoscimenti di leadership nel Grid® Report, nell'Relationship Index e nel Mid-Market Grid® Report per Pharma e Biotech. Inoltre, Kneat si è classificata al secondo posto nell'Usability Index Pharma e Biotech di G2, dimostrando una forte performance in amministrazione, facilità d'uso e soddisfacimento dei requisiti.
Kneat (OTCQX: KSIOF), líder en digitalización de validación y procesos de calidad, ha obtenido las mejores posiciones en los informes de la categoría de Pharma y Biotech Software de G2 en su Fall 2025. La empresa logró liderazgos en tres categorías con una impresionante Puntuación de Satisfacción G2 de 98/100, superando a la segunda clasificada por 20 puntos.
La compañía obtuvo reconocimiento de liderazgo en el Grid® Report, el Relationship Index y el Mid-Market Grid® Report para Pharma y Biotech. Además, Kneat quedó en segundo lugar en el Usability Index Pharma y Biotech de G2, demostrando un rendimiento sólido en administración, facilidad de uso y cumplimiento de requisitos.
Kneat (OTCQX: KSIOF)은 품질 프로세스의 검증 및 디지털화 분야의 선두주자로서, G2의 2025년 가을 Pharma 및 Biotech 소프트웨어 부문 보고서에서 최고 순위를 차지했습니다. 이 회사는 세 가지 부문에서 리더십을 확보했고, 인상적인 G2 만족도 점수 98/100으로 2위 회사를 20포인트 앞질렀습니다.
또한, 그리드(Grid®) 보고서, Relationship Index, Mid-Market Grid® Report에서 Pharma 및 Biotech 분야의 리더십 인정을 받았으며, G2 Pharma 및 Biotech Usability Index에서 2위를 차지해 관리, 사용 편의성 및 요구사항 이행에서 강한 성과를 보여주었습니다.
Kneat (OTCQX: KSIOF), leader dans la validation et la digitalisation des processus qualité, a obtenu des positions de premier plan dans les rapports de l'automne 2025 de G2 pour le logiciel Pharma et Biotech. L'entreprise a occupé des positions de leadership dans trois catégories avec un impressionnant Score de satisfaction G2 de 98/100, dépassant de 20 points la deuxième entreprise classée.
L'entreprise a reçu des recognitions de leadership dans le Grid® Report, l'Relationship Index et le Mid-Market Grid® Report pour Pharma et Biotech. De plus, Kneat s'est classée deuxième dans l'Usability Index Pharma et Biotech de G2, démontrant une forte performance en administration, facilité d'utilisation et satisfaction des exigences.
Kneat (OTCQX: KSIOF), ein Branchenführer bei Validierung und Digitalisierung von Qualitätsprozessen, erreicht Spitzenpositionen in den G2 Fall 2025 Pharma und Biotech Software-Berichten. Das Unternehmen sicherte Führungspositionen in drei Kategorien mit einer beeindruckenden G2-Zufriedenheitsbewertung von 98/100, 20 Punkte vor dem Zweitplatzierten.
Das Unternehmen erhielt Führungsanerkennung im Grid® Report, im Relationship Index und im Mid-Market Grid® Report für Pharma und Biotech. Zudem belegte Kneat den zweiten Platz im G2 Usability Index Pharma und Biotech, was eine starke Leistung in Verwaltung, Benutzerfreundlichkeit und Anforderungserfüllung demonstriert.
كينيت (OTCQX: KSIOF)، الرائد في الرقمنة والتحقق من جودة العمليات، حققت مراكز رائدة في تقارير G2 لفصل خريف 2025 لبرمجيات الأدوية والتكنولوجيا الحيوية. حققت الشركة مراكز قيادية في ثلاث فئات مع درجة رضا G2 تبلغ 98/100، متفوقة بنقاط 20 عن الشركة الثانية في الترتيب.
وحازت الشركة على تقدير القيادة في Grid® Report، وRelationship Index، وMid-Market Grid® Report لقطاع الأدوية والتكنولوجيا الحيوية. بالإضافة إلى ذلك، جاءت Kneat في المركز الثاني في G2 Usability Index Pharma and Biotech، مما يدل على أداء قوي في الإدارة وسهولة الاستخدام وتلبية المتطلبات.
Kneat（OTCQX: KSIOF），在验证与质量流程数字化方面的领军企业，已在 G2 2025 年秋季 Pharma 与 Biotech 软件类别报告中获得领先地位。该公司在三个类别中获得领导地位，且以令人印象深刻的 G2 满意度分数 98/100 超越第二名 20 分。
公司在 Pharma 与 Biotech 的 Grid® Report、Relationship Index、Mid-Market Grid® Report 获得领导力认定。此外，Kneat 在 G2 Pharma 与 Biotech Usability Index 中位列第二，展示了在管理、易用性及需求满足方面的强劲表现。
- Achieved exceptional G2 Satisfaction Score of 98/100, outperforming competitors by 20 points
- Secured leadership position in three major G2 software category reports
- Strong performance in customer relationship metrics including ease of doing business and support quality
- High ranking in usability metrics, indicating strong product market fit
- None.
Score based on User Satisfaction and Market Presence significantly exceeds peers
Limerick, Ireland--(Newsfile Corp. - September 24, 2025) - kneat.com, inc. (TSX: KSI) (OTCQX: KSIOF), a leader in digitizing and automating validation and quality processes, has been awarded the top position in three of G2 Software Review's Fall 2025 Pharma and Biotech Software category reports. Kneat was recognized as:
- Leader in the Grid® Report for Pharma and Biotech
- Leader in the Relationship Index for Pharma and Biotech
- Leader in the Mid-Market Grid® Report for Pharma and Biotech.
Kneat achieved a total G2 Satisfaction Score of 98 out of 100, 20 points higher than the second-ranked company's score of 78.
Grid from Fall 2025 G2 Grid® Report for Pharma and Biotech
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/11876/267637_kneatimg1.jpg
"Earning three G2 leader badges is no small feat for a software company supporting any industry, let alone one as demanding and precise as life sciences," said Eddie Ryan, CEO of Kneat. "The achievement reflects not only the trust that our customers place in us, but the dedication of our team to deliver Kneat's pioneering user-focused software. At Kneat, customer satisfaction isn't just a value — it's at the heart of everything we do. I am proud of our team for embracing this mission every single day."
Kneat's top rating in the G2 Pharma and Biotech Relationship Index is based on customer feedback across categories "Ease of Doing Business," "Likely to Recommend," and "Quality of Support." Kneat was also rated 2nd overall in the G2 Pharma and Biotech Usability Index measuring customer feedback on "Ease of Admin," "Ease of Use" and "Meets Requirements."
G2 scores are based on validated reviews from industry professionals utilising factors such as a company's review count, web presence, growth, influence and engagement. As the largest and most trusted software marketplace, G2 offers
About Kneat
Kneat Solutions provides leading companies in highly regulated industries with unparalleled efficiency in validation and compliance through its digital validation platform Kneat Gx. As an industry leader in customer satisfaction, Kneat boasts an excellent record for implementation, powered by our user-friendly design, expert support, and on-demand training academy. Kneat Gx is an industry-leading digital validation platform that enables highly regulated companies to manage any validation discipline from end-to-end. Kneat Gx is fully ISO 9001 and ISO 27001 certified, fully validated, and 21 CFR Part 11/Annex 11 compliant. compliance standard. Independent customer studies have shown Kneat Gx to reduce labor hours associated with validation documentation by more than
For further information:
Katie Keita, Kneat Investor Relations
P: + 1 902-450-2660
E: investors@kneat.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/267637
FAQ
What recognition did Kneat (KSIOF) receive in the G2 Fall 2025 reports?
How did Kneat's G2 satisfaction score compare to competitors in Fall 2025?
What specific areas did Kneat excel in according to the G2 Fall 2025 reports?
How does G2 determine its software rankings and scores?
